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We present a case of fatal rebound hyperkalemia in a patient with thyrotoxic periodic paralysis (TPP) 
treated with potassium supplementation. Although TPP is a rare hyperthyroidism-related endocrine 
disorder seen predominantly in men of Asian origin, the diagnosis should be considered in patients of 
non-Asian origins presenting with hypokalemia, muscle weakness or acute paralysis. The condition 
may present as a life threatening emergency and unfamiliarity with the disease could result in a fatal 
outcome. Immediate therapy with potassium chloride supplementation may foster a rapid recovery of 
muscle strength and prevent cardiac arrhythmias secondary to hypokalemia, but with a risk of rebound 
hyperkalemia. [West J Emerg Med. 2010; 11(1):57-59.]
INTRODUCTION
Hypokalemic paralysis is a rare cause of muscle 
weakness and cardiac arrhythmias that primarily affects 
male patients of Asian descent. Because it is rare in non-
Asians1 it can be misdiagnosed. Thyrotoxic periodic paralysis 
(TPP) is caused by a sudden shift of potassium into cells, 
leading to hypokalemia and muscle weakness and can lead 
to near-fatal or fatal arrhythmias. Immediate therapy with 
potassium chloride supplementation may foster a rapid 
recovery from weakness and prevent arrhythmias but risks 
rebound hyperkalemia.1,2 We present a case of fatal rebound 
hyperkalemia in a patient with TPP treated with potassium.
CASE REPORT
A 40-year-old Hispanic woman called 911 for worsening 
chest tightness, generalized weakness and vomiting of two 
days. On arrival, paramedics performed an EKG that revealed 
sustained monomorphic ventricular tachycardia at 160-180 
beats/minute. Blood pressure and oxygen saturation were 
normal. She was treated with 40 mg intravenous lidocaine 
after which she converted to normal sinus rhythm. In the 
emergency department (ED), she was alert and complained 
of weakness of all four extremities. She denied shortness 
of breath. She had a history of hyperthyroidism and 
hypertension but took no medicines. Vital signs were blood 
pressure of 126/70 mm of Hg, pulse of 90 beats/minute and 
respiratory rate of 18 breaths/minute. She was afebrile, and 
oxygen saturation was 96% in room air. Cardiac and lung 
examinations were normal. There was no thyromegaly. 
Neurological examination showed 2/6 strength and hypoactive 
reflexes in all four extremities. Cranial nerves and sensations 
were normal. Initial laboratory tests showed potassium 
of 2.3 mEq/L (normal: 3.5-5.5mEq/L) with normal anion 
gap. Magnesium, chloride, calcium and creatinine were 
normal. Urinary toxicology screen was negative. A 12-lead 
electrocardiogram showed normal sinus rhythm. 
In the ED the patient received 40 mEq of oral potassium 
chloride, and intravenous (IV) potassium was started at 20 
mEq/hour. Repeat laboratory testing after three hours showed 
potassium of 1.9 mEq/L. Thyroid-stimulating hormone was 
low (0.01µunit/ml; normal: 0.5-5.0 µunit/ml) with high free 
thyroxine (7.77 ng/dL; normal: 0.75 to 1.8 ng/dL). The patient 
complained of worsening weakness in her legs. She was given 
additional 40 mEq of oral potassium. Potassium was increased 
to 30 mEq/hour IV, and the patient was admitted to medical 
intensive care unit. 
A diagnosis of TPP was made based on clinical 
presentation and laboratory results. Blood drawn after eight 
hours showed potassium of 6.6 mEq/L. Intravenous potassium 
was stopped, and intravenous dose of 1 gm calcium, 50% 
solution of 50 ml dextrose, and 10 units of insulin were given 
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developed episodes of ventricular fibrillation and despite 
several attempts at electrical cardioversion, she died. Her 
potassium level was 10.1 mEq/L at the time of her death.
DISCUSSION
In the United States, the incidence of TPP in the non-
Asian population is 0.1-0.2%.3 It occurs mostly during 
summer and winter and with increased consumption of sweet 
drinks, outdoor activities and exercise. TPP primarily occurs 
in persons aged 20-40, and the most common symptoms are 
leg muscle weakness, aching cramps and stiffness. Although 
most patients with thyrotoxicosis are female, men with 
TPP outnumber women approximately 20:1.1 While TPP is 
associated with hyperthyroidism, personal or family history of 
hyperthyroidism may be absent. As in the case of our patient, 
nearly half of patients with TPP have no obvious symptoms 
related to hyperthyroidism during an attack.1-5 
Differential diagnosis of TPP includes familial periodic 
paralysis (FMPP), barium intoxication, hypochloremic 
metabolic alkalosis and hyperchloremic metabolic acidosis.1,2 
In contrast to TPP, FMPP occurs most often in Caucasians 
and early in life (rarely after age 25).6 And also in contrast to 
FMPP, TPP does not occur during exercise but in a period of 
rest after exercise.1 Barium intoxication should be considered 
and could result from the ingestion of contaminated food 
causing hypokalemia by blocking the potassium channels in 
the cell membrane that normally allow cellular potassium to 
diffuse into the extracellular fluid.7
In the ED, a diagnosis of TPP should be considered 
in men of Asian or Hispanic descent who present with 
hypokalemia, muscle weakness or paralysis and cardiac 
arrhythmias. Leg weakness, which usually begins proximally, 
is most commonly symmetrical and can progress to flaccid 
quadriplegia.1 Deep tendon reflexes are decreased or absent, 
but ocular, bulbar, and respiratory muscles are usually 
spared, as are sensation and level of consciousness, although 
ventilator impairment has been reported.6 The EKG findings 
are those of hypokalemia with increased P wave amplitude, 
prolonged PR interval, widened QRS complexes, and 
prolonged QT and U waves. These EKG findings were absent 
in our patient. Life-threatening intraventricular conduction 
abnormalities and ventricular fibrillation also have been 
reported.8 Urgent blood investigations in the ED should 
include a thyroid function test, and patient should have 
continuous EKG monitoring.
Although the pathogenesis of TPP remains unclear, it 
is believed to be related to increase in sodium-potassium-
adenosine triphosphate (Na/K-ATPase) pump activity. 
Thyroid hormone coupled with enhanced beta adrenergic 
response in thyrotoxicosis state increases Na/K-ATPase 
activity, leading to influx of potassium into the intracellular 
space causing hypokalemia.9 High carbohydrate diet in the 
setting of a hyperadrenergic state in TPP stimulates insulin 
release from pancreatic beta cells, which in turn stimulates 
N/K-ATPase activity.1 The chemical structure of thyroxine 
is similar to catecholamines and exerts its cellular effect via 
catecholamine receptors. This may explain the usefulness of 
nonselective beta blockers in the treatment of TPP-associated 
hypokalemia.1,10,11
A patient with a serum potassium concentration of 2 
mEq/L may have a 400 to 800 mEq potassium deficit.12 The 
serum potassium concentration can rise acutely by as much as 
1 to 1.5 mEq/L after an oral dose of 40 to 60 mEq, and by 2.5 
to 3.5 mEq/L after 135 to 160 mEq.13 Our patient had received 
approximately 240 mEq of potassium (oral and IV) in eight 
hours. We expected our patient would have a potassium level 
of 3.5-4.5 mEq/L after receiving 200 mEq of potassium after 
eight hours. But due to rebound hyperkalemia, potassium 
levels increased to 10.1 mEq/L. This discrepancy between the 
expected calculated potassium and the real potassium is in 
part caused by the fact that during the recovery phase of TPP, 
potassium release from muscle occurs at the rate of up to 15 
mEq/hr.14
Body potassium stores are normal in patients with TPP.12 
A few studies have looked at potassium replacement in TPP. 
In a case-controlled study by Lu et al.,15 average recovery 
time was cut in half in patients with intravenous potassium 
chloride supplementation at the rate of 10 mEq/h vs controls 
(6.3±3.8 vs 13.5±7.5 hr). Rebound hyperkalemia occurred 
in 70% of patients 2-3 hours after recovery from TPP treated 
with IV potassium chloride while rebound hyperkalemia was 
rarely seen with potassium supplementation of 50 mEq or less 
as a total dose. In a retrospective study, Manoukian et al.16 
reported that rebound hyperkalemia occurred in approximately 
40% of patients with TPP, especially if more than 90 mEq of 
potassium chloride was given within 24 hours.16
An alternative approach focusing on treating the 
adrenergic drive has been reported using beta blockade. Both 
oral and IV propranolol appear to be effective in reversing 
TPP without risk of rebound hyperkalemia.10,11,17 Controlled 
studies are needed to document the effectiveness of combined 
nonselective beta-blockers and low-dose potassium.
CONCLUSION
TPP appears to present a problem in potassium 
distribution rather than potassium deficiency; hence, we 
believe that in most patients potassium supplementation is 
not indicated, unless the patient is having life-threatening 
arrhythmias due to hypokalemia or is experiencing respiratory 
insufficiency. The risk of life-threatening arrhythmias 
caused by the potential of rebound hyperkalemia outweighs 
the morbidity of the temporary paralysis. If potassium 
supplementation must be used, as in the case of unstable 
arrhythmias due to hypokalemia, very low doses should 
be given (less than 10 mEq/ hr) with close monitoring of 
potassium level to reduce the risk of rebound hyperkalemia.15
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